Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MPLT vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DSGN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

DSGN Overall Winner 6-Pillar Tally: MPLT 2 – 2 DSGN (2 Tie) Matrix Metrics: MPLT 1 – 4 DSGN

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MPLT carries a Unified Composite Score of 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MPLT vs DSGN
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 78% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $7.44 · SMA50: $9.21
DSGN NASDAQ Head-to-Head Winner
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59

6-Pillar Scorecard Institutional Category Breakdown (MPLT 2 – 2 DSGN)

Columns: Metric · MPLT · DSGN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DSGN
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $33,000
Market Cap $392.9M $677.5M
3. Profitability & Quality DSGN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -111.5% -36.9%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) -$175M -$59M
Cash Flow Margin N/A N/A
Net Cash / Leverage $70M Net Cash $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MPLT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 92.5% (8th %ile) 92.0% (13th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MPLT (1) vs DSGN (4)
Institutional Metric MPLT DSGN Criterion Row Edge
Market Capitalization
Scale
$392.9M $677.5M Larger Scale DSGN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-111.5% -36.9% Higher ROE DSGN
52-Week Range Position
Momentum
3% ($6–$40) 30% ($7–$17) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.05β · 78% Vol 1.32β · 61% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 49.9 / 100 (HOLD) Higher Composite MPLT
Trailing 12M Revenue (USD)
Operating Scale
N/A $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$175M ($70M Net Cash) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DSGN +6.28 pp
MPLT: -9.87% · DSGN: -3.59%
3M Horizon DSGN +6.38 pp
MPLT: -41.29% · DSGN: -34.91%
6M Horizon DSGN +66.71 pp
MPLT: -73.81% · DSGN: -7.1%
1Y Horizon DSGN +92.19 pp
MPLT: -51.4% · DSGN: +40.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPLT vs DSGN. Trailing 12-month operating profitability (MPLT 0.0% vs DSGN 0.0%) and valuation multiples (MPLT N/M vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-111.5% · N/M
DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MPLT BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 92.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MPLT vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MPLT carries a Unified Composite Score of 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DSGN leads the Growth & Scale pillar: MPLT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MPLT generates N/A in USD-normalized revenue versus $33,000 for DSGN. In operating R&D and SG&A reinvestment, MPLT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

MPLT and DSGN trade at balanced relative valuation multiples. MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPLT (-111.5% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.